Core Insights - Lexicon Pharmaceuticals presented a post-hoc analysis of sotagliflozin's efficacy among older adults at the ESC 2025 Congress, highlighting improvements in heart failure endpoints and major adverse cardiovascular events (MACE) [1][2][3] Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program for genomics target discovery [8] Study Details - The analysis pooled data from two pivotal Phase 3 studies, SCORED and SOLOIST-WHF, involving nearly 12,000 participants, with approximately 70% aged 65 or older [2][4] - The primary endpoint was total cardiovascular death, hospitalization for heart failure, or urgent visits for heart failure, with additional endpoints including total MACE [2] Efficacy Results - Sotagliflozin reduced the primary endpoint rate compared to placebo: 8.5 vs 11.8 events per 100 person-years (HR: 0.72) overall, and 8.9 vs 12.4 events per 100 person-years (HR: 0.73) for those aged 65 and older [5] - Total MACE was similarly reduced with sotagliflozin: 5.7 vs 7.1 events per 100 person-years (HR: 0.80) overall, and 5.9 vs 7.4 events per 100 person-years (HR: 0.80) for those aged 65 and older [6] Future Research Directions - Future research may focus on the benefits of sotagliflozin in heart failure patients with preserved ejection fraction (HFpEF), a demographic that is generally older and includes more women [3]